Dashboard
Manage Tickers

ZVRA ZEVRA THERAPEUTICS, INC.

Nasdaq kempharm.com


$ 9.01 $ 0.29 (3.29 %)    

Monday, 10-Nov-2025 18:56:09 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 623.95 $ 4.38 (0.71 %)
DIA $ 474.19 $ 1.94 (0.41 %)
SPY $ 681.80 $ 4.15 (0.61 %)
TLT $ 89.45 $ -0.02 (-0.02 %)
GLD $ 378.75 $ 2.40 (0.64 %)
$ 9.1
$ 8.90
$ 8.88 x 5
$ 9.19 x 25
$ 8.51 - $ 9.23
$ 6.19 - $ 13.16
2,261,168
na
512.31M
$ 4.26
$ 14.50
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-05-2025 09-30-2025 10-Q
2 08-12-2025 06-30-2025 10-Q
3 05-13-2025 03-31-2025 10-Q
4 03-12-2025 12-31-2024 10-K
5 11-13-2024 09-30-2024 10-Q
6 08-13-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 04-01-2024 12-31-2023 10-K
9 11-07-2023 09-30-2023 10-Q
10 08-14-2023 06-30-2023 10-Q
11 05-15-2023 03-31-2023 10-Q
12 03-07-2023 12-31-2022 10-K
13 11-10-2022 09-30-2022 10-Q
14 08-12-2022 06-30-2022 10-Q
15 05-12-2022 03-31-2022 10-Q
16 03-30-2022 12-31-2021 10-K
17 11-10-2021 09-30-2021 10-Q
18 08-13-2021 06-30-2021 10-Q
19 05-13-2021 03-31-2021 10-Q
20 03-12-2021 12-31-2020 10-K
21 10-30-2020 09-30-2020 10-Q
22 08-12-2020 06-30-2020 10-Q
23 05-13-2020 03-31-2020 10-Q
24 02-28-2020 12-31-2019 10-K
25 11-14-2019 09-30-2019 10-Q
26 08-13-2019 06-30-2019 10-Q
27 05-14-2019 03-31-2019 10-Q
28 03-01-2019 12-31-2018 10-K
29 11-09-2018 09-30-2018 10-Q
30 08-10-2018 06-30-2018 10-Q
31 05-11-2018 03-31-2018 10-Q
32 03-30-2018 12-31-2017 10-K
33 11-09-2017 09-30-2017 10-Q
34 08-10-2017 06-30-2017 10-Q
35 05-22-2017 03-31-2017 10-Q
36 03-10-2017 12-31-2016 10-K
37 11-10-2016 09-30-2016 10-Q
38 08-11-2016 06-30-2016 10-Q
39 05-13-2016 03-31-2016 10-Q
40 03-16-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

canaccord-genuity-maintains-buy-on-zevra-therapeutics-lowers-price-target-to-24
Canaccord Genuity Maintains Buy on Zevra T...
11/06/2025 20:16:08

Canaccord Genuity analyst Sumant Kulkarni maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the price target ...

cantor-fitzgerald-maintains-overweight-on-zevra-therapeutics-lowers-price-target-to-24
Cantor Fitzgerald Maintains Overweight on ...
11/06/2025 15:00:40

Cantor Fitzgerald analyst Kristen Kluska maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Overweight and lowers the price t...

zevra-therapeutics-q3-eps-001-beats-004-estimate-sales-26063m-miss-26628m-estimate
Zevra Therapeutics Q3 EPS $(0.01) Beats $(...
11/05/2025 21:14:38

Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(...

earnings-scheduled-for-november-5-2025
Earnings Scheduled For November 5, 2025
11/05/2025 11:12:12

top-stocks-with-earnings-this-week-joby-ionq-amd-and-more
Top Stocks With Earnings This Week: Joby, ...
11/03/2025 14:14:07

Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Fr...

why-pepgen-shares-are-trading-higher-by-112-here-are-20-stocks-moving-premarket
Why PepGen Shares Are Trading Higher By 11...
09/25/2025 10:11:08

Shares of PepGen Inc. (NASDAQ: PEPG) rose sharply in pre-market trading after the company announced the launch of an underwritt...

zevra-therapeutics-presents-several-posters-highlighting-new-data-on-miplyffa-for-treatment-of-niemann-pick-disease-type-c-at-iciem
Zevra Therapeutics Presents Several Poster...
09/04/2025 11:33:27

New data from pre-specified analysis shows patients on concomitant miglustat who switched from placebo to MIPLYFFA experienced ...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
09/03/2025 21:06:23

zevra-therapeutics-to-present-four-posters-on-miplyffa-at-iciem-2025
Zevra Therapeutics To Present Four Posters...
08/28/2025 11:32:02

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for p...

watching-zevra-therapeutics-traders-circulate-unconfirmed-rumor-suggesting-the-co-is-seeing-a-buyout-proposal
Watching Zevra Therapeutics; Traders Circu...
08/21/2025 14:42:47

crude-oil-down-1-performance-food-group-earnings-top-views
Crude Oil Down 1%; Performance Food Group ...
08/13/2025 19:19:46

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
08/13/2025 17:06:22

jmp-securities-maintains-market-outperform-on-zevra-therapeutics-lowers-price-target-to-18
JMP Securities Maintains Market Outperform...
08/13/2025 14:27:37

JMP Securities analyst Jason N. Butler maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Market Outperform and lowers the pr...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
08/13/2025 12:08:29

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
08/12/2025 21:07:08

zevra-therapeutics-q2-eps-124-beats-113-estimate-sales-2590m-beat-2249m-estimate
Zevra Therapeutics Q2 EPS $1.24 Beats $1.1...
08/12/2025 20:09:22

Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly earnings of $1.24 per share which beat the analyst consensus estimate of $1...

Core News & Articles
Earnings Scheduled For August 12, 2025
08/12/2025 08:32:28

a-look-at-zevra-therapeuticss-upcoming-earnings-report
A Look at Zevra Therapeutics's Upcoming Ea...
08/11/2025 15:03:31

zevra-therapeutics-has-submitted-a-marketing-authorization-application-to-the-european-medicines-agency-for-the-evaluation-of-arimoclomol-for-niemann-pick-disease-type-c
Zevra Therapeutics Has Submitted A Marketi...
07/28/2025 10:06:06

The EMA will review the application under the centralized marketing authorization procedure. If a marketing authorization is gr...

zevra-therapeutics-to-present-three-posters-on-miplyffa-and-one-on-olpruva-annual-sergg-2025
Zevra Therapeutics To Present Three Poster...
07/18/2025 11:32:07

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for p...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION